Results 91 to 100 of about 3,719,428 (257)

A Review of Boron Neutron Capture Therapy: Its History and Current Challenges

, 2022
MECHANISM OF ACTION: External beam, whether with photons or particles, remains as the most common type of radiation therapy. The main drawback is that radiation deposits dose in healthy tissue before reaching its target.
Seldon, Crystal, Butkus, Michael, Sauerwein, Wolfgang, Giap, Huan B., Jin, Will H., Wolfgang Sauerwein, Will H. Jin, MD, Huan B. Giap, Crystal Seldon, Wolfgang Sauerwein, MD, Huan B. Giap, MD, PhD, Michael Butkus, Will H. Jin, Crystal Seldon, MD, Michael Butkus, PhD   +14 more
core   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Acute toxicities in proton therapy for head and neck cancer – A matched analysis of the DAHANCA 35 feasibility study

Clinical and Translational Radiation Oncology
Background and purpose: As preparation for a national randomized study comparing proton radiotherapy to photon radiotherapy, DAHANCA 35, we performed a non-randomized pilot study to investigate patient selection, logistics, planning, and treatment ...
K. Nowicka-Matus, J. Friborg, C.R. Hansen, M. Bernsdorf, U.V. Elstrøm, M. Farhadi, C. Grau, J.G. Eriksen, J. Johansen, M.S. Nielsen, A. Holm, E. Samsøe, P. Sibolt, B. Smulders, K. Jensen   +14 more
doaj   +1 more source

[Proton therapy and particle accelerators].

Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics, 2012
Since the high energy accelerator plan was changed from a 40 GeV direct machine to a 12GeV cascade one, a 500 MeV rapid cycling booster synchrotron was installed between the injector linac and the 12 GeV main ring at KEK, National Lab. for High Energy Physics. The booster beams were used not only for injection to the main ring but also for medical use.
openaire   +2 more sources

Particle Radiotherapy [electronic resource] : Emerging Technology for Treatment of Cancer /

, 2016
The results of decades of research and development are providing compelling evidence about the efficacy of radiation therapy with proton and carbon ion beams to achieve superior complication free tumor control leading to a world-wide rapid growth in ...
Lomax, Antony (author), SpringerLink (Online service), Sahoo, Narayan.editor.edthttp://id.loc.gov/vocabulary/relators/edt, Rath, Arabinda Kumar.editor.edthttp://id.loc.gov/vocabulary/relators/edt   +3 more
core   +1 more source

Cyclotrons for Particle Therapy [PDF]

, 2017
In particle therapy with protons a cyclotron is one of the most used particle accelerators. Here it will be explained how a cyclotron works, some beam dynamics aspects, its major subsystems, as well as the advantages and disadvantages of a cyclotron for ...
Schippers, Jacobus Maarten, Schippers, J.M. (author)   +1 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Spread-out Bragg peak FLASH: quantifying normal tissue toxicity in a murine model

Frontiers in Oncology
ObjectiveA favorable effect of ultra-high dose rate (FLASH) radiation on normal tissue-sparing has been indicated in several preclinical studies. In these studies, the adverse effects of radiation damage were reduced without compromising tumor control ...
Line Kristensen, Line Kristensen, Line Kristensen, Per Rugaard Poulsen, Per Rugaard Poulsen, Eleni Kanouta, Eleni Kanouta, Sky Rohrer, Christina Ankjærgaard, Claus E. Andersen, Jacob G. Johansen, Jacob G. Johansen, Yuri Simeonov, Uli Weber, Cai Grau, Cai Grau, Brita Singers Sørensen, Brita Singers Sørensen, Brita Singers Sørensen   +18 more
doaj   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source